Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Blue Cross & Blue Shield of MississippiCommercial · Coverage · Medical Policy · MS · Cardiology, GeneticsMedium impact

KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy

Effective date
Not stated in the notice
Identified
Jun 20, 2026

Summary

KIF6 genotyping is considered investigational for predicting cardiovascular risk and/or the effectiveness of statin therapy. The policy states that KIF6 Trp719Arg genotyping is being evaluated as a test to predict the risk of future cardiovascular events and response to statin therapy, and that there is no strong evidence that the KIF6 protein plays a direct biologic role in atherosclerosis or coronary artery disease. In 2011 the FDA found that the data submitted for Celera's KIF6 Genotyping Assay were insufficient to demonstrate its safety and effectiveness, and it indicated that clinical utility data, possibly from a randomized controlled trial, might be required.

Get alerts when payers change rules like this one

We check Blue Cross & Blue Shield of Mississippi and other payers every day and email you when a change matches your specialty and state.

Get Blue Cross & Blue Shield of Mississippi alertsPolicy Monitoring is free. No card required.

What to do

Action · 3 steps
01Stop scheduling or billing KIF6 genotyping for predicting cardiovascular risk or the effectiveness of statin therapy, because the policy considers it investigational.
02Under the policy guidelines, investigational technology is not considered medically necessary.
03The policy lists no policy exceptions.

Codes mentioned

8147984999

Original notice

KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy
bcbsms.com · Always check the source before changing claims.
View original ↗

Related changes

See all Blue Cross & Blue Shield of Mississippi changes →
Somatic Biomarker Testing (Including Liquid Biopsy) for Targeted Treatment in Non-Small-Cell Lung Cancer (EGFR, ALK, BRAF, ROS1, RET, MET, KRAS, NTRK)MediumNo effective date · Medical PolicyMolecular Genomic Profiling for Cancers of Unknown PrimaryMediumNo effective date · Medical PolicyMiscellaneous Genetic and Molecular Diagnostic TestsMediumEffective Jul 1, 2025 · Medical PolicyGenotyping for 9p21 Single Nucleotide Polymorphisms to Predict Risk of Cardiovascular Disease or AneurysmMediumNo effective date · Medical PolicyBrowse every Blue Cross & Blue Shield of Mississippi change in the policy list

Related policy hubs

Blue Cross & Blue Shield of Mississippi policiesMS policy changesCardiologyGeneticsCode 81479Code 84999

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account